3 terminated, 1 completed, 1 unknown. 2 Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Pulmonary Inflammation: new trials by email Literature Review of Pulmonary Inflammation trials Research Report on Pulmonary Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Inhaled SNSP113, Inhaled Placebo - Lung Diseases, Pulmonary Disease | Phase 1 | Terminated | Synspira, Inc. | 32 | 2017-09-28 | 2018-05-25 |
| Pulmonary and Systemic Effects of Exposure to Wood Smoke Wood smoke exposure - Pulmonary Inflammation, Cytotoxicity | Unknown | Umeå University | 20 | 2017-06-14 | 2017-10-04 | |
| Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis Lactobacillus rhamnosus, Placebo - Pulmonary Inflammation, Cystic Fibrosis | Not applicable | Terminated | Cantonal Hospital of St. Gallen | 68 | 2013-02-22 | 2025-06-13 |
| Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 CTX-4430, Mannitol, Placebo - Pulmonary Inflammation | Phase 1 | Completed | Celtaxsys, Inc. | 96 | 2012-12-01 | 2013-09-10 |
Pneumonia (5) · Cystic Fibrosis (2) · Burkholderia Infections (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Dyspnea (1) · Heart Failure (1) · Infections (1) · Lung Diseases (1) · Mycobacterium Infections, Nontuberculous (1) · Myocardial Infarction (1) · Pulmonary Edema (1) · Respiratory Distress Syndrome (1)
Respiratory Tract Infections (5) · Infections (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Genetic Diseases, Inborn (2) · Infant, Newborn, Diseases (2) · Pancreatic Diseases (2) · Actinomycetales Infections (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Coronaviridae Infections (1) · Gram-Negative Bacterial Infections (1) · Gram-Positive Bacterial Infections (1)
Mannitol (1) · VIP-ELP fusion molecule PB1046 (1) · acebilustat (1)
Cantonal Hospital of St. Gallen (1) · Celtaxsys, Inc. (1) · PhaseBio Pharmaceuticals Inc. (1) · Synspira, Inc. (1) · Umeå University (1)
Australia (1) · Sweden (1) · Switzerland (1) · United Kingdom (1) · United States (1)
Ala Muala, MD, PhD (1) · Janakan Krishnarajah, MB, BS FRACP (1) · Maria Theresa Basco, MD, MPH (1)